Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Flotations versus blank cheques
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Big caps bounce back for biopharma
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.